Upregulation of MEK2 can activate the ERK signaling pathway, promoting clear cell renal cell carcinoma progression, and elevated levels of MEK2 in tissues are associated with lower survival rates in patients (43). This evidence concerns the gene MAP2K2 and clear cell renal carcinoma.